On Feb. 23, the American Cancer Society announced that AstraZeneca has committed $2.8 million toward the American Cancer Society’s Navigation Capacity-Building Initiative Grant Program. The program is part of ACS’ commitment to enhancing oncology patient navigation and addressing barriers to individualized, timely, and equitable care for cancer patients and their families.

Patient navigation is one of the only evidence-based interventions to effectively help eliminate health disparities and improve health equity across the cancer continuum. ACS and AstraZeneca’s continued partnership will help expand access to patient navigation by addressing barriers to individualized, timely, and equitable means of entry to care for cancer patients.

“Strategic partnerships have always been critical in our goal to end cancer as we know it, for everyone. We are excited to have the support of our longtime partner, AstraZeneca, to strengthen our patient support navigation programs,” said Chief Executive Officer Dr. Karen E. Knudsen. “These programs are critical in addressing health inequities for cancer patients, especially those that face the greatest barriers to care.”

For more than 15 years, ACS and AstraZeneca have collaborated in developing and growing ACS’ Patient Navigation programs. Most recently, AstraZeneca awarded ACS with an additional $250,000 grant to expand the Health Equity Ambassadors network. The network helps increase cancer prevention, early detection education, and community collaboration within medically underserved populations to deliver critical cancer-related information and resources.

Visit the ACS News Room to view the press announcement and help amplify this exciting news by engaging on LinkedIn and Twitter.